The Beneluxa Initiative’s Post

The #Beneluxa Initiative announces successful conclusion of #Libmeldy price negotiations, directly benefiting patients in three countries. As members of the Beneluxa Initiative, Ireland, Belgium and the Netherlands, have successfully concluded joint pricing negotiations for Libmeldy, a treatment designed for Metachromatic Leukodystrophy (MLD), having arrived at a mutually agreeable pricing arrangement with the manufacturer Orchard Therapeutics.   #MLD is a rare disease affecting an estimated 1 in 40,000 – 160,000 people. Its effects are devastating to those suffering with it and their families. Children with MLD will directly benefit from this agreement as Libmeldy will become available for reimbursement in the three countries.   The negotiations were carried out based on a joint Health Technology Assessment (HTA) procedure involving the three countries, showcasing the effectiveness of a unified approach in ensuring equitable #access to innovative therapies. The outcome of successive negotiations with the manufacturer has shown that #collaboration through the Beneluxa Initiative can support positive outcomes for countries and, in particular, for patient access to the latest medications. Access to Libmeldy through this multi-country agreement is a testament to the collaborative spirit driving the Beneluxa Initiative.   Read more on statements of the Ministers on our website: https://lnkd.in/d_nh5ZfY